Bridge Biotherapeutics Inc
Parataxis Korea, Inc., a clinical stage biotech company, engages in the development of therapeutics for the treatment of ulcerative colitis, fibrotic diseases, and cancers worldwide. Its products in pipeline includes BBT-401, a Pellino-1 inhibitor, which is in Phase I clinical trial for the treatment of ulcerative colitis; and BBT-877, an autotaxin inhibitor that is in Phase I clinical trial for … Read more
Bridge Biotherapeutics Inc (288330) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.042x
Based on the latest financial reports, Bridge Biotherapeutics Inc (288330) has a cash flow conversion efficiency ratio of -0.042x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-2.02 Billion) by net assets (₩48.42 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Bridge Biotherapeutics Inc - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Bridge Biotherapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Bridge Biotherapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bridge Biotherapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Climeon AB (publ)
OTCGREY:CLMOF
|
-0.038x |
|
MSC Co. Ltd
KQ:009780
|
0.048x |
|
Kaya Holdings Inc
OTCQB:KAYS
|
0.025x |
|
YONGHE MED.GR.DL-0000025
F:L97
|
N/A |
|
Y.H. Dimri Construction & Development Ltd
TA:DIMRI
|
-0.148x |
|
Cimentas Izmir Cimento Fabrikasi TAS
IS:CMENT
|
0.007x |
|
Green Plus Co. Ltd
KQ:186230
|
0.075x |
|
IAR SA
RO:IARV
|
N/A |
Annual Cash Flow Conversion Efficiency for Bridge Biotherapeutics Inc (2016–2024)
The table below shows the annual cash flow conversion efficiency of Bridge Biotherapeutics Inc from 2016 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩26.25 Billion | ₩-20.72 Billion | -0.789x | +51.87% |
| 2023-12-31 | ₩19.38 Billion | ₩-31.78 Billion | -1.640x | -111.66% |
| 2022-12-31 | ₩51.87 Billion | ₩-40.18 Billion | -0.775x | -57.85% |
| 2021-12-31 | ₩43.05 Billion | ₩-21.13 Billion | -0.491x | -122.97% |
| 2020-12-31 | ₩59.23 Billion | ₩-13.04 Billion | -0.220x | -114.54% |
| 2019-12-31 | ₩75.02 Billion | ₩-7.70 Billion | -0.103x | -161.25% |
| 2018-12-31 | ₩-45.95 Billion | ₩-7.70 Billion | 0.168x | -76.47% |
| 2017-12-31 | ₩-10.81 Billion | ₩-7.70 Billion | 0.712x | -89.34% |
| 2016-12-31 | ₩-1.15 Billion | ₩-7.70 Billion | 6.677x | -- |